The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Brophy Gerard since 2020.
This trader's CIK number is 1776107.
At the time of last reporting, Brophy Gerard was the EVP, Biopharma Production of Avantor, Inc.. (stock ticker symbol AVTR).
Also see all insider trading activities at Avantor, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2023 | AVTR | 0 | $0 | 18,312 | $458,480 | 0 | $0 |
2022 | AVTR | 0 | $0 | 95,658 | $3,655,135 | 59,418 | $1,096,262 |
2021 | AVTR | 0 | $0 | 573,063 | $17,629,789 | 538,892 | $12,110,736 |
2020 | AVTR | 0 | $0 | 25,495 | $442,593 | 0 | $0 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2023-03-03 | AVTR | Sale | 3,914 | 25.00 | 97,850 |
2023-02-27 | AVTR | Sale | 3,059 | 25.00 | 76,475 |
2023-02-02 | AVTR | Sale | 11,339 | 25.06 | 284,155 |
2022-05-20 | AVTR | Sale | 19,603 | 31.27 | 612,985 |
2022-03-01 | AVTR | Sale | 2,027 | 34.47 | 69,870 |
2022-02-23 | AVTR | Sale | 3,059 | 33.79 | 103,363 |
2022-01-03 | AVTR | Option Ex | 59,418 | 18.45 | 1,096,262 |
2022-01-03 | AVTR | Sale | 59,418 | 40.77 | 2,422,471 |
2022-01-05 | AVTR | Sale | 11,551 | 38.65 | 446,446 |
2021-07-30 | AVTR | Option Ex | 81,125 | 23.20 | 1,882,100 |
2021-07-30 | AVTR | Sale | 81,125 | 37.24 | 3,021,095 |
2021-05-20 | AVTR | Sale | 19,603 | 31.10 | 609,653 |
2021-02-24 | AVTR | Sale | 3,059 | 27.93 | 85,437 |
2021-02-22 | AVTR | Option Ex | 19,769 | 17.67 | 349,318 |
2021-02-22 | AVTR | Sale | 19,769 | 28.62 | 565,788 |
2021-01-11 | AVTR | Sale | 378,580 | 30.06 | 11,380,114 |
2021-01-11 | AVTR | Option Ex | 378,580 | 23.20 | 8,783,056 |
2021-01-06 | AVTR | Sale | 11,509 | 27.24 | 313,505 |
2021-01-04 | AVTR | Option Ex | 59,418 | 18.45 | 1,096,262 |
2021-01-04 | AVTR | Sale | 59,418 | 27.84 | 1,654,197 |
2020-05-20 | AVTR | Sale | 25,495 | 17.36 | 442,593 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Brophy Gerard (EVP, Biopharma Production of Avantor, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.